Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.
Also called NCT04534114
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 307 participants
- Sponsor
- Registry
-
NCT04534114 -
2019-003927-39
-
- Other papers using this trial's data
- A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, Japan, Latvia, Russia, South Korea, Spain, Taiwan, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT04534114. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-04 (actual); primary completion 2022-01-24 (actual). Results posted on 2023-07-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug
- Acronym
- RE-THINc ESRD
- Condition
- End Stage Renal Disease Requiring Hemodialysis
- Intervention (Drug)
- Fesomersen sodium (BAY2976217)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct04534114- Content hash
19f69abeda6115efd242fa242f683e846b70536740d26923cc9ee95550235ce8